SciELO - Scientific Electronic Library Online

vol.67 número4Emergencias extrahospitalarias: el paciente suicida índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Sanidad Militar

versión impresa ISSN 1887-8571


JUBERIAS SANCHEZ, A. et al. Risk management in the transfer of manufacturing processes: Application to the manufacturing of oseltamivir tablets in the swine flu pandemic. Sanid. Mil. [online]. 2011, vol.67, n.4, pp.334-344. ISSN 1887-8571.

Introduction: Risks management applied to the pharmaceutical industry, through their identification, evaluation and control, is a useful tool to guarantee drug quality. The declaration of swine flu H1N1 pandemic in 2009 by the World Health Organization, resulted in the need to transform into tablets part of the strategic reserves of oseltamivir phosphate of the Ministry of Health and Social Policy and the Autonomous Communities. This situation led to a change in the activity of the Defense Pharmaceutical Service under the auspices of the Spanish Agency for Medicines and Health Products. Objective: Applying the principles of risk management makes possible a fast adaptation of the technology to manufacture the oseltamivir phosphate tablets. We evaluated the risk associated to the different stages of the process and established particular control parameters of the final quality of the product. Materials and Methods: We applied the modal analysis of failures and effects and their criticality to establish and evaluate possible risks of the manufacturing process and carried out the necessary lab tests to check the quality of the product. Results: The risks associated to the process are established and evaluated. The average tablet content and the dissolution percentage at 20 minutes is 101.9% and 102.5%, respectively. All batches passed the microbiological contamination control. The results obtained for all batches in the validating variables of the process (weight of the tablets, percentages of active principle, homogeneity of the mix and dissolution) fulfill the required specifications and there are not significant differences among the different batches (p>0,05). Conclusions: The results confirm the successful transfer of the manufacturing process of the oseltamivir phosphate tablets to the facilities and equipment available, as well as the achievement of a robust and repetitive process that provides a drug fulfilling the required quality specifications.

Palabras clave : Risk management; Process transfer; Equipment adaptation; Antivirals; Oseltamivir phosphate.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons